These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 4943934)

  • 1. Binding of 5,5-diphenylhydantoin and its major metabolite to human and rat plasma proteins.
    Conard GJ; Haavik CO; Finger KF
    J Pharm Sci; 1971 Nov; 60(11):1642-6. PubMed ID: 4943934
    [No Abstract]   [Full Text] [Related]  

  • 2. The relationship of 5,5-diphenylhydantoin metabolism to the species-specific induction of gingival hyperplasia in the rat.
    Conard GJ; Haavik CO; Finger KF
    Arch Oral Biol; 1972 Feb; 17(2):311-21. PubMed ID: 4502048
    [No Abstract]   [Full Text] [Related]  

  • 3. Relationship of drug metabolism and inflammation to the gingival response of rats treated with diphenylhydantoin.
    Conard GJ; Osborn JC; Pekary AD; Scholle RH
    J Dent Res; 1975 Jun; 54 Spec No B():B68-74. PubMed ID: 1055746
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of protein binding on the distribution of 5,5-diphenylhydantoin between plasma and red cells.
    Borondy P; Dill WA; Chang T; Buchanan RA; Glazko AJ
    Ann N Y Acad Sci; 1973 Nov; 226():82-7. PubMed ID: 4520405
    [No Abstract]   [Full Text] [Related]  

  • 5. [Histopathological study on diphenylhydantoin gingival hyperplasia in rats, especially the role of gingival inflammation in diphenylhydantoin gingival hyperplasia].
    Watanabe H
    Nihon Shishubyo Gakkai Kaishi; 1982 Sep; 24(3):385-408. PubMed ID: 6962259
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma protein binding of diphenylhydantoin in man.
    Lunde KM
    Acta Pharmacol Toxicol (Copenh); 1971; 29 Suppl 3():152-5. PubMed ID: 5316396
    [No Abstract]   [Full Text] [Related]  

  • 7. Gingival hyperplasia and diphenylhydantoin.
    Ciancio SG; Yaffe SJ; Catz CC
    J Periodontol; 1972 Jul; 43(7):411-4. PubMed ID: 4504524
    [No Abstract]   [Full Text] [Related]  

  • 8. Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding.
    Odar-Cederlöf I; Borgå O
    Eur J Clin Pharmacol; 1974; 7(1):31-7. PubMed ID: 4852619
    [No Abstract]   [Full Text] [Related]  

  • 9. Levels of 5,5-diphenylhydantoin and its major metabolite in human serum, saliva, and hyperplastic gingiva.
    Conard GJ; Jeffay H; Boshes L; Steinberg AD
    J Dent Res; 1974; 53(6):1323-9. PubMed ID: 4529919
    [No Abstract]   [Full Text] [Related]  

  • 10. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.
    Reidenberg MM; Odar-Cederlöf I; von Bahr C; Borgå O; Sjöqvist F
    N Engl J Med; 1971 Jul; 285(5):264-7. PubMed ID: 4378402
    [No Abstract]   [Full Text] [Related]  

  • 11. Diphenylhydantoin gingival hyperplasia in Macaca arctoides: a new human model.
    Staple PH; Reed MJ; Mashimo PA
    J Periodontol; 1977 Jun; 48(6):325-36. PubMed ID: 405470
    [No Abstract]   [Full Text] [Related]  

  • 12. Gingival hyperplasia related to treatment with diphenylhydantoin (diphedan; DH).
    Rudas SL; Bárdos FV
    Int Z Klin Pharmakol Ther Toxikol; 1969 Apr; 2(2):180-4. PubMed ID: 4308214
    [No Abstract]   [Full Text] [Related]  

  • 13. Distribution and metabolism of diphenylhydantoin in oral and nonoral tissues of ferrets.
    Steinberg AD; Allen PM; Jeffay H
    J Dent Res; 1973; 52(2):267-70. PubMed ID: 4511308
    [No Abstract]   [Full Text] [Related]  

  • 14. Dilantin and folic acid status. Clinical implications for the periodontist.
    Mallek HM; Nakamoto T
    J Periodontol; 1981 May; 52(5):255-9. PubMed ID: 6941010
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma protein binding, plasma concentrations, and effects of diphenylhydantoin in man.
    Lund L; Lunde PK; Rane A; Borga O; Sjöqvist F
    Ann N Y Acad Sci; 1971 Jul; 179():723-8. PubMed ID: 4998913
    [No Abstract]   [Full Text] [Related]  

  • 16. Altered protein binding of diphenylhydantoin in uremic plasma.
    Blum MR; Riegelman S; Becker CE
    N Engl J Med; 1972 Jan; 286(2):109. PubMed ID: 5006870
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.
    Lunde PK; Rane A; Yaffe SJ; Lund L; Sjöqvist F
    Clin Pharmacol Ther; 1970; 11(6):846-55. PubMed ID: 4394754
    [No Abstract]   [Full Text] [Related]  

  • 18. Diphenylhydantoin-induced gingival overgrowth in man: a clinico-pathological study.
    Peñarrocha-Diago M; Bagán-Sebastián JV; Vera-Sempere F
    J Periodontol; 1990 Sep; 61(9):571-4. PubMed ID: 2213467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Case of gingival hyperplasia due to diphenylhydantoin].
    Bella G; Rossetti B; Greco S; Indelicato F
    Minerva Stomatol; 1987 May; 36(5):367-71. PubMed ID: 3476825
    [No Abstract]   [Full Text] [Related]  

  • 20. [Gingival hyperplasia due to diphenylhydantoin. Anatomo-clinical study of a case].
    Latorre G; Carrozza G; Busà S; Calabrò S; Briguglio R
    Stomatol Mediterr; 1986; 6(4):483-8. PubMed ID: 2955528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.